Lv63
2200 积分 2023-02-22 加入
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
14天前
已完结
Prevalence of Monoclonal Gammopathy of Undetermined Significance in an Apparently Healthy Yixing Population in Mainland China
1个月前
已完结
中国多发性骨髓瘤诊治指南（2020年修订）
2个月前
已完结
急性肾损伤的研究进展
2个月前
已完结
2019年新型抗肿瘤药物相关肾脏损伤研究进展
2个月前
已关闭
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
2个月前
已完结
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
2个月前
已完结
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
2个月前
已完结
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
2个月前
已完结
皖公网安备34019202002308
